Sylvia Lopes Maia Teixeira

Sylvia Lopes Maia Teixeira

Auto-generated profile, based on publicly available information

Sylvia Lopes Maia Teixeira

Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (IOC-Fiocruz), Rio de Janeiro, RJ, Brazil

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2017 in Retrovirology
Verified
Journal Article
Open access
PDF file
SASuwellen de Azevedo
Suwellen de Azevedo
DCDiogo Gama Caetano
Diogo Gama Caetano
FCFernanda Heloise Côrtes
Fernanda Heloise Côrtes
STSylvia L. M. Teixeira
Sylvia L. M. Teixeira
KSKarina dos Santos Silva
Karina dos Santos Silva
GBGonzalo Bello
Gonzalo Bello
Ongoing intra-host HIV-1 evolution has been shown in individuals that naturally suppress the viremia to low levels (HIV controllers) by the analysis of the RNA in plasma compartment. Detection of evolution at the DNA proviral compartment in HIV controllers, however, has been more challenging and the precise correlation between the systemic viral suppression level and rate of reservoir’s reseeding in those individuals is not fully understood. In this sense, we examined the proviral DNA quasispecies by single genome amplification of the env gene in a cohort of 23 HIV controllers from Brazil, divided in three groups, according to the level of systemic viral suppression: (1) elite controllers with persistent undetectable viral load (PEC, n = 6); (2) elite controllers with occasional episodes of transient (51–400 copies/mL) viremia (EEC, n = 7); and (3) viremic controllers with persistent low-level (80–2000 copies/mL) viremia (VC, n = 10). The HIV-1 diversity of the PBMC-associated proviral quasispecies in EC was significantly (P < 0.01) lower than in VC, but not significantly different between PEC and EEC groups. We detected a considerable variation in the average pairwise nucleotide distance and proportion of unique sequences in the HIV-1 proviral quasispecies of PEC and EEC. Some PEC and EEC displayed highly homogenous proviral populations with large clusters of identical sequences, while others exhibited relatively diverse proviral populations with a high proportion of unique sequences comparable to VC subjects. The long-term (10–15 years) follow-up of the HIV-1 proviral populations revealed a complete evolutionary stasis in one PEC and measurable divergence rates in one EEC [3.1 (1.2–5.6) × 10−3 substitutions/site/year and one VC [2.9 (0.7–5.1) × 10−3 substitutions/site/year]. There is no simple relationship between systemic viral suppression and intra-host proviral diversity or rate of reservoir’s reseeding in chronically infected HIV controllers. Our results demonstrate that very divergent patterns of intra-host viral diversity and divergence could be detected in the setting of natural suppression of HIV-1 replication and that ongoing evolution and reseeding of the PBMC proviral reservoir occurs in some elite controllers.

2 December 2023 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
TTThiago S. Torres
Thiago S. Torres
STSylvia L.M. Teixeira
Sylvia L.M. Teixeira
BHBrenda Hoagland
Brenda Hoagland
KKKelika Anne Konda
Kelika Anne Konda
MDMonica Derrico
Monica Derrico
MEMaria Eguiluz
Maria Eguiluz
HIV incidence estimation is critical for monitoring the HIV epidemic dynamics and the effectiveness of public health prevention interventions. We aimed to identify sexual and gender minorities (SGM) with recent HIV infections, factors associated with recent HIV infection, and to estimate annualised HIV incidence rates. Cross-sectional multicentre study in HIV testing services in Brazil and Peru (15 cities). Inclusion criteria: 18+ years, SGM assigned male at birth, not using pre-/post-exposure prophylaxis. We identified recent HIV infection using the Maxim HIV-1 LAg-Avidity EIA assay as part of a recent infection testing algorithm (RITA). Annualized HIV incidence was calculated using the UNAIDS/WHO incidence estimator tool. Multivariable logistic regression models were used to estimate factors associated with recent HIV infection. Trial registration: NCT05674682. From 31-Jan-2021 to 29-May-2022, 6899 individuals participated [Brazil: 4586 (66.5%); Peru: 2313 (33.5%)]; 5946 (86.2%) cisgender men, 751 (10.9%) transgender women and 202 (2.9%) non-binary/gender diverse. Median age was 27 (IQR: 23–34) years. HIV prevalence was 11.4% (N = 784/6899); 137 (2.0%) SGM were identified with recent HIV infection. The overall annualized HIV incidence rate was 3.88% (95% CI: 2.86–4.87); Brazil: 2.62% (95% CI: 1.78–3.43); Peru: 6.69% (95% CI: 4.62–8.69). Participants aged 18–24 years had higher odds of recent HIV infection compared to those aged 30+ years in both countries. Our results highlight the significant burden of HIV epidemic among SGM in large urban centres of Brazil and Peru. Public health policies and interventions to increase access to effective HIV prevention methods such as PrEP are urgently needed in Latin America. Unitaid, 10.13039/100004423 WHO (Switzerland), 10.13039/100009647 Ministry of Health from Brazil and Peru.

12 December 2018 in Retrovirology
Verified
Journal Article
Open access
PDF file
HPHury Hellen Souza de Paula
Hury Hellen Souza de Paula
AFAna Cristina Garcia Ferreira
Ana Cristina Garcia Ferreira
DCDiogo Gama Caetano
Diogo Gama Caetano
EDEdson Delatorre
Edson Delatorre
STSylvia Lopes Maia Teixeira
Sylvia Lopes Maia Teixeira
FCFernanda Heloise Côrtes
Fernanda Heloise Côrtes
To investigate the impact of early combined antiretroviral therapy (cART) on inflammation biomarkers and immune activation during acute and early chronic HIV-1 infection. We included 12 acute (AHI), 11 early chronic (EcHI), and 18 late chronic HIV-1-infected (LcHI) individuals who were treated with cART and 18 HIV-1-uninfected (HIV-neg) individuals. Plasmatic levels of inflammation biomarkers, CD8+CD38+HLA-DR+ T cell frequencies, CD4 T cell counts, CD4/CD8 ratio, total HIV-1 DNA and plasmatic viral load were evaluated. Mann–Whitney test, Pearson and Spearman correlation, and linear regression models were used for statistical analyses. IP-10, IL-18, and sCD163 were significantly elevated at pre-ART in the AHI and EcHI groups, showing a significant reduction after 6 months of cART in the AHI group, achieving similar levels to the HIV-neg group. For the EcHI group, the IP-10 and sCD163 levels were also significantly reduced on M6-ART; however, IP-10 levels remained higher than in the HIV-neg group, and no significant reduction of IL-18 levels was observed. The CD8+ T cell activation levels were elevated in the AHI and EcHI groups at pre-ART and showed a significant reduction on M6-ART, but they were similar to levels seen for HIV-neg only after 12 months of cART. At pre-ART, IP-10 levels but not IL-18 levels were positively correlated with HIV-1 viral load in the AHI group. Early initiation of cART in HIV infection can reduce systemic inflammation, but the earlier normalization of the inflammation markers was only observed when cART was initiated in the acute phase of infection. A slower dynamic of reduction was observed for CD8+ T cell activation.

10 April 2014 in Genes & Immunity
Verified
Journal Article
Open access
STS L M Teixeira
S L M Teixeira
NSN B R de Sá
N B R de Sá
DCD P Campos
D P Campos
ACA B Coelho
A B Coelho
MGMonick Lindenmeyer Guimarães
Monick Lindenmeyer Guimarães
MMM G Morgado
M G Morgado
Several human leukocyte antigen (HLA) class I alleles are associated with the susceptibility to human immunodeficiency virus-1 (HIV-1) infection and/or AIDS progression. Of these, the HLA-B alleles are considered the strongest genetic determinant of disease outcome. We evaluated the influence of the HLA-B alleles on AIDS progression among HIV-1-positive individuals from Rio de Janeiro, Brazil, who were categorized as rapid progressors (RPs), typical progressors (TPs) or long-term non-progressors (LTNPs). In this study, significant differences in HLA-B allele frequencies were observed among the three progression groups for the B*48, B*49 and B*52 alleles. After controlling for other factors associated with AIDS progression, the presence of the B*52 allele was shown to be a significant protective factor (hazard ratio (HR) 0.49 (95% confidence interval (CI) 0.27–0.90) P<0.03). Although no direct association was observed between the presence of the B*27 or B*57 allele and the LTNP profile compared with the TP or RP groups, the adjusted model confirmed that these alleles are protective factors against AIDS progression (HR 0.62 (95% CI 0.38–0.99) P<0.05), as previously described. These data corroborate the existence of significant differences in HLA-B allele frequencies among the distinct AIDS progression profiles and further elucidate the role of HLA alleles in the outcome of HIV infections in diverse populations.

1 January 2023 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
TTThiago Silva Torres
Thiago Silva Torres
STSylvia L. M. Teixeira
Sylvia L. M. Teixeira
BHBrenda Hoagland
Brenda Hoagland
KKKelika A. Konda
Kelika A. Konda
MDMonica Derrico
Monica Derrico
IGImPrEP Seroincidence Study Group
ImPrEP Seroincidence Study Group
Background: HIV incidence estimation is critical for monitoring the HIV epidemic dynamics and the effectiveness of public health prevention interventions. We aimed to identify recent HIV infections and associated factors, and to estimate annualized HIV incidence rates. Methods: Cross-sectional multicenter study in HIV testing services in Brazil and Peru (15 cities). Inclusion criteria: 18+ years, sexual and gender minorities (SGM) assigned male at birth, not using pre-/post-exposure prophylaxis. We identified recent HIV infection using the Maxim HIV-1 LAg-Avidity EIA assay as part of a recent infection testing algorithm (RITA). Annualized HIV incidence was calculated using the UNAIDS/WHO incidence estimator tool. Multivariable logistic regression models were used to estimate factors associated with recent HIV infection. Trial registration: NCT05674682. Findings: From 31-Jan-2021 to 29-May-2022, 6899 individuals participated [Brazil: 4586 (66·5%); Peru: 2313 (33·5%)]; 5946 (86·2%) cisgender men who have sex with men, 751 (10·9%) transgender women and 202 (2.9%) non-binary/gender diverse. Median age was 27 (IQR:23-34) years. HIV prevalence was 11·4% (N=784/6899); 137 (17·5%) were classified as recent HIV infection. The overall annualized HIV incidence rate was 3·88% (95%CI:3·40-4·36); Brazil: 2·62% (95%CI:2·14-3·10); Peru: 6·69% (95%CI:5·57-7·81). Participants aged 18-24 years had higher odds of recent HIV infection compared to 30+ years in both countries. Interpretation: High levels of recent HIV infection and incidence rate among SGM in Brazil and Peru highlight the burden of the HIV epidemic in these populations. Public health policies and interventions to increase access to effective HIV prevention methods such as PrEP are urgently needed in Latin America. Trial Registration: The study was registered at ClinicalTrials.gov, NCT05674682. Funding: Unitaid, WHO, Ministry of Health from Brazil and Peru. Declaration of Interest: Nothing to declare. Ethical Approval: Institutional review boards at Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (Rio de Janeiro, Brazil; #CAAE:20012619.9.1001.5262) and Universidad Peruana Cayetano Heredia (Lima, Peru; #104717) approved the study. Ethical approvals were also obtained from the WHO Research Ethics Review Committee ERC and local IRB at each Brazilian site. All study participants provided written informed consent in Portuguese (Brazil) or Spanish (Peru) before enrollment.

1 July 2009 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
STSylvia Lopes Maia Teixeira
Sylvia Lopes Maia Teixeira
FBFrancisco Inácio Bastos
Francisco Inácio Bastos
MHMariana A. Hacker
Mariana A. Hacker
MMMariza Gonçalves Morgado
Mariza Gonçalves Morgado